Clinical trials: Liver Cirrhosis, Biliary
Primary Biliary Cholangitis (PBC)
Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC)
The goal of this clinical trial is to learn what happens to PVT201 when it enters your body and how it affects your immune system. It will also learn about the safety of PVT201 after a single dose.
- Trial name
- NCT06798454
- Testing
- PVT201
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Parvus Therapeutics, Inc.
Hepatitis, Autoimmune, Primary Biliary Cholangitis
Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II
A randomized controlled open-label clinical trial of ursodeoxycholic acid combined with low dose glucocorticoid in the treatment of PBC With AIH Features II to asses efficacy and safety.
- Trial name
- NCT04617561
- Testing
- Ursodeoxycholic acid, Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- West China Hospital
Primary Biliary Cirrhosis
Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis
The purpose of this study was to determine if OCA had an effect on cholesterol levels in the blood in participants with primary biliary cirrhosis (PBC).
- Trial name
- NCT01865812
- Testing
- Obeticholic Acid
- Where
- 7 sites in United States
- Volunteers
- 27 people
- Sponsor
- Intercept Pharmaceuticals
Cirrhosis, Hepatocellular Carcinoma
Microbiota Study in Liver Transplanted Patients
Many studies describe the relationship between microbiota alteration and the occurrence of metabolic, alcoholic or inflammatory liver diseases.
- Conditions
- Cirrhosis, Hepatocellular Carcinoma, Liver Transplant, Microbiota
- Trial name
- BIM-LT (NCT03507140)
- Testing
- Multiple sampling
- Where
- France
- Volunteers
- 64 people
- Sponsor
- University Hospital, Grenoble
Orphan Cholestatic Liver Diseases, Progressive Familial Intrahepatic Cholestasis
An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects
The primary objectives of the study are to assess the mass balance recovery after a single dose of carbon-14 [14C]-A4250 as a capsule and to provide plasma, urine and faecal samples for metabolite profiling and structural…
- Conditions
- Orphan Cholestatic Liver Diseases, Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Primary Biliary Cirrhosis
- Trial name
- NCT03082937
- Testing
- 3 mg [14C]-A4250 capsule
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Albireo
Primary Biliary Cholangitis
A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
A Randomized, Double-Blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of CS0159 in Patients with Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid…
- Trial name
- NCT07282353
- Testing
- 2mg CS0159
- Where
- 42 sites in China
- Volunteers
- 135 people
- Sponsor
- Cascade Pharmaceuticals, Inc
Primary Biliary Cholangitis (PBC)
A Study of Fatigue, Itching and Daily Activities in People With Primary Biliary Cholangitis Starting Elafibranor
The purpose of this study is to understand how tiredness changes in adults with Primary Biliary Cholangitis (PBC) after starting elafibranor in routine clinical practice.
- Trial name
- NCT07906639
- Testing
- Elafibranor
- Volunteers
- 50 people
- Sponsor
- Ipsen
Primary Biliary Cirrhosis
Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)
Up to 40% of patients with PBC have an inadequate response to standard treatment with UDCA, hence bezafibrate, a PPAR-agonist is being introduced as add-on therapy in these patients.
- Trial name
- NCT04514965
- Testing
- Blood sampling, Fibroscan, Question
- Where
- 2 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- University of Aarhus
Primary Biliary Cholangitis
RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)
The purposes of this study are to evaluate the treatment effect of seladelpar on composite biochemical improvement in cholestasis markers based on ALP and total bilirubin and to evaluate the safety of seladelpar over 12 months of…
- Trial name
- NCT04620733
- Testing
- Seladelpar 10 mg, Seladelpar 5 mg
- Where
- 134 sites in United States, Argentina and 24 more
- Volunteers
- 193 people
- Sponsor
- Gilead Sciences
Liver Failure, Liver Diseases, Alcoholic
BRIDGE Device for Post-operative Pain Control
Auricular neurostimulation is a potential novel and non-invasive method of pain control following liver transplantation in a growing patient population with the probability of significant impact on economics and morbidity.
- Conditions
- Liver Failure, Liver Diseases, Alcoholic, Liver Diseases, Pain, Postoperative
- Trial name
- BRIDGE (NCT03265249)
- Testing
- BRIDGE device
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Duke University
Liver Disease, Cholestasis
Gabapentin to Treat Itch in Patients With Liver Disease
In this study, the effect of the medication gabapentin to treat itching secondary to liver disease is being studied. There are some funds to cover travel expenses for patients who are not from New York (NY).
- Conditions
- Liver Disease, Cholestasis, Cirrhosis, Pruritus
- Trial name
- NCT00058890
- Testing
- Gabapentin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Primary Bilary Cirrhosis (PBC)
Clinical Characterization of Patients With Primary Biliary Cirrhosis Treated With Seladelpar in the Real-life Setting
The seladelpar registry will collect real-world data of patients with PBC diagnosis treated with seladelpar in the real-life scenario in Germany and Switzerland.
- Trial name
- SENSE registry (NCT07549607)
- Where
- 21 sites in Germany, Switzerland
- Volunteers
- 100 people
- Sponsor
- University of Leipzig
Biliary Cirrhosis, Primary
Family Studies in Primary Biliary Cirrhosis (PBC)
Primary biliary cirrhosis (PBC) is a chronic liver disease primarily affecting middle age women. It is characterized by immune-mediated damage to cells lining the tiny bile ducts within the liver.
- Trial name
- NCT00242125
- Where
- Canada
- Volunteers
- 3,000 people
- Sponsor
- University Health Network, Toronto